REMEDIUM

С 1 июля в России стала обязательной цифровая маркиров- ка лекарственных препаратов, данные о движении которых на всех этапах должны вноситься в систему маркировки. Проверить легальность конкретной упаковки теперь может любой желающий с помощью приложения «Честный знак» посредством сканирования кода Data Matrix, нанесенногона упаковку.

The commercial sector of the Russian pharmaceutical market at the first half year-end 2020. The coronavirus infection epidemic, surely, has become one of the central themes of the beginning of the year. In the first half of 2020, the commercial sector of the Russian pharmaceutical market grew by 5% in terms of roubles as compared to the same period last year, but in dollar terms, the growth rates were much lower (-0.5%).

Artificial Intelligence (AI) is increasingly making inroads in our life and becomes an integral part of modern business. In accordance with the Decree of the President of the Russian Federation “On the Development of Artificial Intelligence in the Russian Federation”, the National Strategy for the Development of Artificial Intelligence for the period until 2030 entered into force in October 2019. This article discusses the growing role of this technology in the transformation of the Russian pharmaceutical sector.

Breast cancer (BC) is the leading oncologic pathology in the female population of Russia, which accounts for 21.1% of all malignant neoplasms in patients [1]. Despite great progress in diagnosis of the disease, detection of breast cancer in late stages is one of the significant problems. In this regard, the improvement of approaches to the treatment of breast cancer, including its metastatic forms, is a highly topical problem of modern medicine.

Introduction. The wide prevalence of diseases of the genitourinary system determines the need to use a variety of tools for their treatment and prevention, including plant-based raw materials.The purpose of the study is to determine the main characteristics and trends in the development of the market of urological medicines and dietary supplements plant-based on raw materials, as well as the competitive positions of foreign and domestic manufacturers in this segment. Research methods. The study was conducted using the DSM Group pharmacy sales database, official sources of information about the registration of medicines and dietary supplements, and clinical recommendations.Results. Pharmacy sales of herbal medicines and dietary supplements used in urology in 2018 amounted to 32 million packages worth14,4 billion rubles in retail prices. Drugs accounts for 78,5% of the market structure in terms of value and 82,8% - in kind. More than half of the total market is occupied by funds used for infectious and inflammatory diseases, where the share of drugs accounts for more than 90%. Russian companies account for 9% of the drugs segment and 64,2% of dietary supplements in value terms.Conclusion. Russian manufacturers occupy relatively weak competitive positions in relation to leading foreign companies due to the use of outdated forms of production, as well as focusing on the dietary supplements market.

Воспалительные заболевания органов малого таза (ВЗОМТ) лидируют в структуре гинекологической заболеваемости, более того, их распространен- ность продолжает расти1.Насколько опасны эти заболевания, кто находится в группе риска и каковы современные подходы к профилактике и лечению ВЗОМТ, мы попросили рассказать Александра ТИХОМИРОВА, д.м.н., профессора кафедры«Акушерство и гинекология» МГМСУ им. А.И. Евдокимова.

Background. Due to ratification of the Decision of the EAC Commission on the circulation of medicinal products, a common EAEU pharmaceutical market will be formed, and registration dossiers will be accepted in electronic form of eCTD in XML format starting from January 1, 2021. It is related to the fact that the EAEU member states will exchange information on medicinal products and their results within the framework of an information integrated system. An application for marketing authorization is now submitted in electronic form in PDF format in accordance with the legislation of the Russian Federation. The XML format has been used in the EU since 2003, but not in the Russian Federation. To continue circulation of authorized medicinal products on the territory of the EAEU, it is necessary to bring the registration dossier in accordance with the requirements of the EAEU by December 31, 2025. Beginning on January 01, 2021, applications for marketing authorization of medicinal products will be only accepted under the legislation of the EAEU. In this regard, Russian enterprises - marketing authorization holders have been tasked with converting all registration dossiers to XTML files. The study is aimed to analyse the market for proposals for installation of software to convert documents to the required format and development recommendations for enterprises - marketing authorization (MA) holders - for making the necessary decisions. Commercial proposals of three software companies were studied and recommendations were developed for enterprises - MA holders within the framework of a situation analysis.Purpose of the study. To analyse the market for proposals for installation of software to convert documents to the required format and development recommendations for enterprises - marketing authorization (MA) holders for making the necessary decisions.Conclusion. The study identified factors that have an impact on the decision-making of the heads of pharmaceutical organizations regarding the choice of proposals for installation of software to convert registration dossier documents to the required format according to the rules of the EAEU. It investigated the consequences of various decisions. Recommendations have been developed for companies - MA holders for submitting an electronic DMF in accordance with the EAEU rules.

Период самоизоляции и карантина стал вызовом для фармацевтической индустрии. Взрывной спрос на одни категории аптечных товаров при практически полном отказе от других, паника и страх, осторожность и надежда на скорейшую стабилизацию ситуации - с этими проблемами в большей или меньшей степени столкнулись аптечные организации и фармацевтические компании многих стран. Личными впечатлениями о непростой ситуации, сложив- шейся во время пандемии COVID-19, с нами поделились эксперты из России и нескольких стран Европы.

This research aims to identify the most effective and prevalent type of advertising and PR-tool used by pharmaceutical companies at com- munity pharmacies. A cross-sectional study design was carried out using the non-repeated random sampling technique in the city of Riyadh (Kingdom of Saudi Arabia). Standardized questionnaires were administered by means of face-to-face interviews or via online software Sphinx. The relative importance of prevalence and the mean evaluation of effectiveness were determined for all studied marketing tools in the differ- ent groups of respondents (pharmaceutical sales representatives, community pharmacists, consumers, and the entire sample). Inter-individual differences in prevalence and evaluation of effectiveness were assessed by computing the coefficient of variation, whereas inter-group differ- ences were determined by one-way analysis of variance (ANOVA) with the Scheffé test as a post-hoc test.Research findings showed that, according to all respondents and to the respondents of certain groups, the most prevalent PR tool in pharma- cies was gifts with company’s logo. The same tool also was rated with the highest mean evaluation as the most effective one in the group of consumers, pharmacists, and all respondents. The most prevalent type of advertising used in community pharmacies was outdoor print adver- tising, and as the most effective was named video indoor advertising, according to the general opinion of all respondents.In conclusion, the results of the present research enable an understanding of which advertising types and PR-tools are commonly used at community pharmacies and which ones are the most effective, mostly influencing consumers’ purchasing decisions.

This article presents a retrospective analysis of clinical, laboratory data, and outcomes in patients with the diagnosis of SARS-CoV-2 infection with severe bilateral pneumonia complicated by acute respiratory distress syndrome.We analyzed the case histories of the patients who received high-flow nasal cannula oxygen therapy at the intensive care unit of the FGBU FNKC FMBA of Russia. 20 patients received standard therapy. 19 patients were additionally prescribed inhaled Surfactant BL 75mg nebulized twice daily for 5 days.This retrospective analysis shows that the administration of an inhaled surfactant before initiating mechanical ventilation can inhibit theprogression of respiratory failure, prevent mechanical ventilation, and improve survival.

Год начался с усиления участия государства в лекарственном обеспечении онкологических и орфанных пациентов, в результате чего в I квартале 2020 г. заметно увеличилась доля государства на фармрынке. Одновременно с этим пандемия коронавирусной инфекции перестала быть чем-то внешним для России и начала кардинально влиять на жизнь в стране. Сначала ее влияние на фарму казалось положительным: в марте, накануне введения режима самоизоляции, произошел резкий скачок спроса на лекарственные препараты. Но вскоре на фоне введенных ограничений упала покупательная способность населения, а за ней и динамика продаж. Однако снижение покупательной способности населения оказалось не главным фактором риска для производителей лекарств в условиях коронавирусной пандемии. Какие трансформации ждут российскую фарму в стремительно меняющейся глобальной экономической реальности, эксперты отрасли обсудили в ходе онлайн-форума «Российский фармацевтический сектор в условиях мировой пандемии» 9 июня.